Pharmacological interventions for stroke: failures and future
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Given the few options currently available for patients following ischaemic stroke, the recent disappointing failures of several large-scale Phase III clinical trials has made the search for novel therapeutic approaches even more critical. Experimental evidence has suggested that the majority of stroke patients have a slow evolution of brain injury which can occur over several hours. Progressive microcirculatory failure following the initial onset of ischaemia may contribute to the expansion of brain injury. Included among the pathophysiological changes that are speculated to occur as a secondary response to the initial ischaemia are free radical production, excitotoxicity (for example, glutamate) disruption of ionic homeostasis (for example, sodium and calcium influx), enzymatic changes, stimulation of the inflammatory process, endothelin release, activation of platelets and leukocytes, delayed coagulation and endothelial dysfunction. All of these pathophysiological reactions could contribute to an increase in local vascular resistance and therefore cause progressive hypoperfusion of the brain following the onset of stroke. The scope of this review will focus on recent clinical failures in addition to agents currently in clinical development, comparing vascular targets to the common neuroprotective strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
Rodriguez-Mateos, A., Vauzour, D., Krueger, C. G., Shanmuganayagam, D., Reed, J., Calani, L., Mena, P., Del Rio, D., & Crozier, A. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1330-7 · Cited by 602
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke
Woodruff, T. M., Thundyil, J., Tang, S.-C., Sobey, C. G., Taylor, S. M., & Arumugam, T. V. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-11 · Cited by 598
Target-based drug discovery: is something wrong?
Sams-Dodd, F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03316-1 · Cited by 522
Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:65 · Cited by 475
A critical role of neural-specific JNK3 for ischemic apoptosis
Kuan, C.-Y., Whitmarsh, A. J., Yang, D. D., Liao, G., Schloemer, A. J., Dong, C., Bao, J., Banasiak, K. J., Haddad, G. G., Flavell, R. A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336254100 · Cited by 409
Metadata
- Authors
- Tuma, R. F., Legos, J. J., & Barone, F. C.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2002-05
- Volume
- 11
- Issue
- 5
- Pages
- 603-614
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2026926066
- Cited by
- 63
- References
- 1
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.